Skip to main content
Equibles

Alyeska Investment Group, L.P.

Position in INAB — In8bio, Inc.

CIK 1453072 CHICAGO, IL
Back to INAB Full portfolio

Position in INAB

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$1,331,489
-$66,103 QoQ
Shares Held
944,319
0.0% QoQ
Ownership
9.58%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1
of 21 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in INAB Over Time

Shares Held

Position Value (USD)

Derivatives in INAB

reported options exposure · as of Dec 31, 2023
CallValue
$1,131,147
CallShares
27,322
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Alyeska Investment Group, L.P. holds $989,063,778 across 83 Biotechnology names. INAB ranks #70 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 659,279 $123,469,771
2 IONS
Ionis Pharmaceuticals Inc
 1,417,916 $112,426,559
3 PTGX
Protagonist Therapeutics, Inc
 889,298 $109,010,148
4 XENE
Xenon Pharmaceuticals Inc.
 697,692 $42,112,689
5 MRNA
Moderna, Inc.
 560,819 $39,274,154
6 KYMR
Kymera Therapeutics, Inc.
 276,455 $31,701,094
7 LBRX
Lb Pharmaceuticals Inc
 863,947 $28,039,399
8 PRAX
Praxis Precision Medicines, Inc.
 80,846 $27,066,432

All Filings in INAB

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,331,489 944,319
2026-03-31 $1,397,592 944,319
2025-12-31 $2,240,512 957,484
2025-09-30 $178,990 82,484
2025-06-30 $172,391 82,484
2025-03-31 $345,209 2,079,575
2024-12-31 $1,301,265 5,063,291
2024-09-30 $117,398 434,809
2024-06-30 $542,933 641,008
2024-03-31 $526,298 446,016
2023-12-31 $1,131,147 819,672
2023-12-31 $1,131,147 819,672